Biolato, Marco http://orcid.org/0000-0002-5172-8208
Bianco, Assunta http://orcid.org/0000-0002-7101-0949
Lucchini, Matteo http://orcid.org/0000-0002-0447-2297
Gasbarrini, Antonio http://orcid.org/0000-0002-6230-1779
Mirabella, Massimiliano http://orcid.org/0000-0002-7783-114X
Grieco, Antonio http://orcid.org/0000-0002-0544-8993
Funding for this research was provided by:
Università Cattolica del Sacro Cuore
Article History
Accepted: 28 June 2021
First Online: 28 July 2021
Declarations
:
: Open access funding provided by Università Cattolica del Sacro Cuore within the CRUI-CARE Agreement.
: A. Bianco reports personal fees and/or travel grants from Sanofi-Genzyme, Novartis, Merck, Roche, Biogen, Almirall. M. Lucchini reports travel grants from Roche, Biogen, Novartis, Almirall, and Sanofi-Genzyme; speaking and/or consulting fees from Biogen, Novartis, Merck-Serono, Sanofi-Genzyme, Bayer, and Almirall. M. Mirabella reports scientific advisory board membership with Bayer Schering, Biogen, Sanofi-Genzyme, Merck, Novartis, Teva; consulting and/or speaking fees, research support or travel grants from Almirall, Bayer Schering, Biogen, CSL Behring, Sanofi-Genzyme, Merck, Novartis, Teva, Roche, Ultragenix; principal investigator in clinical trials for Biogen, Merck, Novartis, Roche, Sanofi Genzyme, Teva, Ultragenix, and CSL Behring. Other authors declare no conflict of interests for this article.
: Not applicable.
: Not applicable.
: Not applicable.
: MB and AB wrote the paper; AB and ML collected the data, AG, MM and AG reviewed the manuscript for important intellectual content. All authors read and approved the final version.